New selective inhibitors of cap dependent proteins: Synthesis, delivery and characterisation (Q84205): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
(Changed label, description and/or aliases in fr: translated_label) |
||
| label / fr | label / fr | ||
Nouveaux inhibiteurs sélectifs des protéines dépendantes du cap: synthèse, livraison et caractérisation | |||
Revision as of 16:23, 30 November 2021
Project Q84205 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | New selective inhibitors of cap dependent proteins: Synthesis, delivery and characterisation |
Project Q84205 in Poland |
Statements
4,500,000.0 zloty
0 references
4,500,000.0 zloty
0 references
100.0 percent
0 references
1 June 2017
0 references
30 November 2021
0 references
UNIWERSYTET WARSZAWSKI
0 references
The project aims at the design, synthesis, and evaluation of novel mRNA 5’ cap analogs as selective inhibitors of three major cap-related proteins: the eukaryotic translation initiation factor 4E (eIF4E) and the two decapping enzymes (DcpS and Dcp2). The proteins were selected due to their key roles in mRNA function and an already-confirmed status as molecular targets for cancer and neuromuscular diseases. To achieve the goal, we propose a comprehensive approach encompassing 1) generation of novel cap derivatives, either by traditional chemical synthesis or by combinatorial approach based on in situ click chemistry, 2) ideas for novel molecular probes and screening approaches specifically tailored for each of the proteins, 3) in-depth evaluation of the found inhibitors using biophysical, biochemical, and structural methods to understand their mechanism of action at the molecular level, 4) application of several cell-delivery strategies to demonstrate the biological potential in vivo. (Polish)
0 references
The project aims at the design, synthesis, and evaluation of novel mRNA 5' cap analogs as selective inhibitors of three major cap-related proteins: the eukaryotic translation initiation factor 4E (eIF4E) and the two decapping enzymes (DCPS and Dcp2). The proteins were selected due to their key roles in mRNA function and an already-confirmed status as molecular targets for cancer and neuromuscular diseases. To achieve the goal, we propose a comprehensive approach encompassing 1) generation of novel cap derivatives, either by traditional chemical synthesis or by combinatorial approach based on in situ click chemistry, 2) ideas for novel molecular probes and screening approaches specifically tailored for each of the proteins, 3) in-depth evaluation of the found inhibitors using biophysical, biochemical, and structural methods to understand their mechanism of action at the molecular level, 4) application of several cell-delivery strategies in the demonstrate. (English)
14 October 2020
0 references
Identifiers
POIR.04.04.00-00-20A2/16
0 references